Motavizumab, A Neutralizing Anti-Respiratory Syncytial Virus (Rsv) Monoclonal Antibody Significantly Modifies The Local And Systemic Cytokine Responses Induced By Rsv In The Mouse Model

Motavizumab (MEDI-524) is a monoclonal antibody with enhanced neutralizing activity against RSV. In mice, motavizumab suppressed RSV replication which resulted in significant reduction of clinical parameters of disease severity. We evaluated the effect of motavizumab on the local and systemic immune...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Mejías, Asunción, Chávez-Bueno, Susana, Raynor, Martin B, Connolly, John, Kiener, Peter A, Jafri, Hasan S, Ramilo, Octavio
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2007
Aiheet:
Short Report
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2222633/
https://ncbi.nlm.nih.gov/pubmed/17961258
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1743-422X-4-109
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia